Chemical structure:

IUPAC name:

Ethyl N-[(2-{[(4-{N‘-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-2-pyridinyl-β-alaninate

CAS number:

211915-06-9

Therapy area:

Anti-coagulant

References:

IH

Status:

Under development

Mechanism of action

Dabigatran (Pradaxa) blocks the thrombin molecule’s active site from activating coagulation factors by forming a reversible bond with it. According to the “Adverse Effects” section, it could not have as strong of an antagonistic impact on thrombin-mediated platelet aggregation. Dabigatran also lessens thrombin-mediated inhibition of fibrinolysis and may consequently potentially improve fibrinolysis. Thrombin can be rendered inactive even when it is attached to fibrin.

DISCLAIMER: PRODUCTS COVERED BY VALID & UNEXPIRED PATENTS ARE NOT OFFERED (OR) SUPPLIED FOR COMMERCIAL SCALE. THE PATENT POSITION SHOULD BE VERIFIED & LIABILITY LIES WITH THE CUSTOMER ONLY. PRODUCTS COVERED BY PATENTS ARE AVAILABLE ONLY FOR R&D USE.